42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
38 citations
,
May 2021 in “International Journal of Infectious Diseases” Low testosterone may indicate severe COVID-19 in men.
27 citations
,
November 2021 in “Scientific Reports” Men are more affected by COVID-19 due to differences in immune responses and protein expression.
24 citations
,
December 2020 in “Kardiologiia” Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.
24 citations
,
August 2020 in “AJGP” A woman's sudden hair loss was linked to her previous COVID-19 infection.
20 citations
,
September 2020 in “Journal of Translational Medicine” Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.
15 citations
,
March 2023 in “BioMed” MIS-A is a severe complication after COVID-19, mostly in young black males, needing more research and awareness.
13 citations
,
October 2021 in “The Journal of Microbiology” Human placenta hydrolysate may help treat COVID-19 by reducing virus replication and boosting immune response.
9 citations
,
May 2021 in “Dermatologic Therapy” Possible link between androgens and COVID-19 severity; more research needed.
7 citations
,
September 2021 in “Dermatology and Therapy” Vaccination is crucial for psoriasis patients on immunosuppressive therapy to manage COVID-19 risks.
5 citations
,
May 2022 in “Bionatura” Asthma and high testosterone increase Covid-19 severity, while progesterone protects young women.
4 citations
,
May 2024 in “Archives of Dermatological Research” Skin symptoms can be a sign of COVID-19 and may worsen with stress.
3 citations
,
February 2022 in “Journal of Infection” People with no symptoms or mild COVID-19 have lower antibody levels, increasing their risk of getting COVID-19 again.
2 citations
,
October 2020 in “Annals of Oncology” Men may be more vulnerable to severe COVID-19 due to genetic and hormonal factors, but more research is needed.
1 citations
,
October 2022 in “The Journal of Dermatology” Hair loss occurred after a COVID-19 infection.
November 2023 in “Klìtinna ta organna transplantologìâ” MSC-derived exosomes can help treat COVID-19, hair loss, skin aging, and arthritis.
September 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Children may have lingering respiratory issues after recovering from COVID-19.
April 2023 in “Journal of Investigative Dermatology” Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
November 2021 in “Journal of the European Academy of Dermatology and Venereology” Skin and mucosal issues can occur after COVID-19 in adults and children.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
August 2021 in “Journal of cosmetic dermatology” The editorial stresses the importance of COVID-19 vaccination and ongoing contributions to the journal.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
123 citations
,
May 2020 in “Drug Development Research” Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
38 citations
,
January 2020 in “Cell Transplantation” Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
9 citations
,
October 2020 in “Journal of the European Academy of Dermatology and Venereology” Children with chilblain-like lesions may have a link to COVID-19.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.